| Excerpt | Relevance | Reference |
|---|
| "Edaravone treatment for up to 14 days suppresses the progression of disuse muscle atrophy and improves leg locomotor function to a greater extent than shorter-term treatment in acute stroke patients." | 9.14 | Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. ( Higashi, Y; Kondo, H; Metoki, N; Moriwaki, H; Naritomi, H; Nishimura, H; Oda, T; Oe, H; Saito, K; Tanahashi, N; Tanaka, K; Terayama, Y; Yamamoto, Y; Yuasa, H, 2010) |
| "Edaravone treatment for up to 14 days suppresses the progression of disuse muscle atrophy and improves leg locomotor function to a greater extent than shorter-term treatment in acute stroke patients." | 5.14 | Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. ( Higashi, Y; Kondo, H; Metoki, N; Moriwaki, H; Naritomi, H; Nishimura, H; Oda, T; Oe, H; Saito, K; Tanahashi, N; Tanaka, K; Terayama, Y; Yamamoto, Y; Yuasa, H, 2010) |